Breast Cancer Somatic Genetics Consortium. Genes Chromosomes Cancer 1999, 25:212–221.PubMedCrossRef 10. Hampton GM, 17-AAG purchase Mannermaa A, Winqvist R, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee WK, Evans GA: Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res 1994, NU7441 ic50 54:4586–4589.PubMed 11. Carter SL, Negrini M, Baffa R, Gillum DR, Rosenberg AL, Schwartz GF, Croce CM: Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Res

1994, 54:6270–6274.PubMed 12. Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, van’t Veer LJ: The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat 2008, 107:243–248.PubMedCrossRef 13. Swift M, Morrell D, Massey RB, Chase CL: Incidence of

cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991, 325:1831–1836.PubMedCrossRef 14. Easton DF: Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994, 66:S177–182.PubMedCrossRef 15. Inskip HM, Kinlen LJ, Taylor AM, Woods CG, Arlett CF: Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 1999, 79:1304–1307.PubMedCrossRef 16. Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996, 92:130–134.PubMedCrossRef 17. Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van’t Veer LJ: ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. PF-6463922 concentration Am J Hum Genet 2000, 66:494–500.PubMedCrossRef 18. Milne RL: Variants

in the ATM gene and breast cancer susceptibility. Genome Medicine 2009., 1: 19. Mehdipour P, Mahdavi M, Mohammadi-Asl J, Atri M: Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer. Medical Oncology 2010, 1–5. 20. Gao LB, Pan SB-3CT XM, Jia J, Liang WB, Rao L, Xue H, Zhu Y, Li SL, Lv ML, Deng W, Chen TY, Wei YG, Zhang L: IL-8 -251A/T polymorphism is associated with decreased cancer risk among population-based studies: evidence from a meta-analysis. Eur J Cancer 2010, 46:1333–1343.PubMedCrossRef 21. Gao LB, Bai P, Pan XM, Jia J, Li LJ, Liang WB, Tang M, Zhang LS, Wei YG, Zhang L: The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010, in press. 22. Gao LB, Pan XM, Li LJ, Liang WB, Zhu Y, Zhang LS, Wei YG, Tang M, Zhang L: RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat 2010, in press. 23. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539–1558.PubMedCrossRef 24. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease.